Looking east for a new HIV drug.China's FusoGen Pharmaceuticals has developed a new HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. fusion inhibitor fusion inhibitor n. A drug that interferes with the entry of HIV into helper T cells by inhibiting the fusion of the viral and cell membranes. that is currently in human clinical trials. The drug has been registered as a new medicine with China's State Food and Drug Administration The State Food and Drug Administration (SFDA Simplified Chinese: 国家食品药品监督管理局) is founded on the basis of the State Drug Administration. . It is modeled on Fuzeon Fu·ze·on A trademark for the drug enfuvirtide. enfuvirtide Fuzeon Pharmacologic class: Human immunodeficiency-1 (HIV-1) fusion inhibitor Therapeutic class: Antiretroviral , the U.S. drug developed and marketed by Roche and Trimeris, but uses a different molecular modeling. The company hopes to have the drug available in China by the end of 2006 and says it will be priced considerably lower than Fuzeon, which costs U.S. HIV patients about $20,000 per year. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion